Founded in 2019, BigHat Biosciences is a Series B biotechnology company in the San Francisco Bay Area. BigHat is led by a team of experts spanning machine learning, molecular biology, drug development, and medicine. BigHat is supported by a cadre of world leaders, including a Nobel Laureate and the physician-scientist that brought Herceptin to market. To date, BigHat has raised $105 million from top investors led by Section 32, Andreessen Horowitz, and 8VC and is quickly succeeding on partnerships with large biopharma partners. In addition to these collaborations, BigHat has active therapeutic programs spanning multiple domains of human health, including inflammation, oncology, and infectious diseases in preclinical studies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/20/22 | $75,000,000 | Series B |
8VC AME Cloud Ventures Amgen Ventures Andreessen Horowitz Bristol-Myers Squibb Gaingels GRIDS Capital Quadrille Capital Section 32  | undisclosed |
